Today's Highlights
Premium
FDA Approval of Johnson & Johnson ICOTYDE™ Ushers in New Era for First-Line Systemic Treatment of Plaque Psoriasis with a Targeted Oral Peptide
Johnson & Johnson in the NEWS March 18, 2026, Johnson & Johnson ( JNJ ) announced today that the FDA has approved ICOTYDE™ ( icotrokinra ), an interleukin-23 ( IL-23 ) receptor antagonist for the trea...
P
Prohost Biotech
1 min read
38
0
Unlock Premium Content
This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.
Unlimited articles
Expert analysis
Research reports
Comments (0)
Please sign in to join the discussion